CLYY.F Stock Overview
A biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.24 |
| 52 Week High | €0.54 |
| 52 Week Low | €0.24 |
| Beta | 1.51 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -66.79% |
| 33 Year Change | -94.81% |
| 5 Year Change | n/a |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLYY.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 5.1% |
| 1Y | -66.8% | 29.2% | 37.7% |
Return vs Industry: CLYY.F underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: CLYY.F underperformed the US Market which returned 35.1% over the past year.
Price Volatility
| CLYY.F volatility | |
|---|---|
| CLYY.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CLYY.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLYY.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 18 | Matt Kane | www.celyad.com |
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets.
Celyad Oncology SA Fundamentals Summary
| CLYY.F fundamental statistics | |
|---|---|
| Market cap | US$29.86m |
| Earnings (TTM) | -US$8.34m |
| Revenue (TTM) | US$77.45k |
385.5x
P/S Ratio-3.6x
P/E RatioIs CLYY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLYY.F income statement (TTM) | |
|---|---|
| Revenue | €72.00k |
| Cost of Revenue | €34.00k |
| Gross Profit | €38.00k |
| Other Expenses | €7.79m |
| Earnings | -€7.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 02, 2025
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 52.78% |
| Net Profit Margin | -10,766.67% |
| Debt/Equity Ratio | 0% |
How did CLYY.F perform over the long term?
See historical performance and comparison